Treatment
➤ The recommendation for the use of the following agent for the
treatment of SSc-ILD is strong:
• Mycophenolate (⊕
, very low confidence in effect estimates)
➤ The recommendation for the use of the following agents for the
treatment of SSc-ILD is conditional:
• Cyclophosphamide (⊕⊕
, low confidence in effect estimates)
• Rituximab (⊕
, very low confidence in effect estimates)
• Tocilizumab (⊕
, very low confidence in effect estimates)
• Nintedanib (⊕
, very low confidence in effect estimates)
• Nintednaib plus mycophenolate (⊕
, very low confidence in effect estimates)
➤ The recommendation for further research due to insufficient
evidence was made for the following agents for the treatment of
SSc-ILD and is strong:
• Pirfenidone (⊕
, very low confidence in effect estimates)
• Pirfenidone plus mycophenolate (⊕
, very low confidence in effect estimates)
➤ Caution must be taken in using systemic corticosteroids in patients
with SSc with or without SSc-ILD. Whenever possible, the daily dose
should not exceed the equivalent of 15 mg prednisone (Best Practice
Statement).
